MaxCyte (MXCT) Q4 2024 earnings summary

Executive summary

• Achieved 9% core revenue growth in 2024 despite a 6% decline in total revenue, driven by strategic initiatives and operational improvements.

• Integrated SeQure Dx, expanding offerings to comprehensive gene editing safety assessments and broadening customer reach.

• Supported the launch of CASGEVY, the first approved non-viral cell therapy using the company's platform.

• Expanded SPL (Strategic Platform License) portfolio to 29 active customers, with 18 active clinical programs and one commercial program; signed a record six SPLs in 2024.

• Ended 2024 with $190.3 million in cash, cash equivalents, and investments.

Financial highlights

• Total revenue for 2024 was $38.6 million, down 6% year-over-year; Q4 revenue was $8.7 million, down 45% from Q4 2023 due to prior year milestone revenue.

• Core revenue for 2024 was $32.5 million, up 9% year-over-year; Q4 core revenue was $8.6 million, up 20% from Q4 2023.

• SPL program-related revenue was $6.1 million for 2024, ahead of guidance but down from $11.5 million in 2023.

• Full year 2024 gross profit was $31.5 million (82% margin); non-GAAP adjusted gross margin was 84%.

• Operating expenses for 2024 were $82.7 million, down from $84.8 million in 2023.

Outlook and guidance

• 2025 core revenue growth expected at 8%-15%, including at least $2 million from SeQure Dx.

• SPL program-related revenue for 2025 forecasted at approximately $5 million.

• Expected to end 2025 with about $160 million in cash and investments.

• Guidance assumes no significant change in the macroeconomic or funding environment.